Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer

BACKGROUND. Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti‐programmed cell death‐1 protein receptor (PD‐1)/programmed cell death‐1 protein ligand (PD‐L1) therapy, but few studies have explored using circulating tumor DNA (ctDNA) TMB in non‐small...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Chae, Young Kwang, Davis, Andrew A., Agte, Sarita, Pan, Alan, Simon, Nicholas I., Iams, Wade T., Cruz, Marcelo R., Tamragouri, Keerthi, Rhee, Kyunghoon, Mohindra, Nisha, Villaflor, Victoria, Park, Wungki, Lopes, Gilberto, Giles, Francis J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2019
Ämnen:
Immuno‐Oncology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656496/
https://ncbi.nlm.nih.gov/pubmed/30867242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0433
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk